Chemoradiation Boosts Survival in Patients With Nasopharynx Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

ASCO--The preliminary results of an Intergroup study of patients with locally advanced nasopharyngeal cancer show a highly significant improvement in survival with the use of chemoradia-tion, compared with radiation alone, Muhyi Al-Sarraf, MD, said at the ASCO plenary session.

ASCO--The preliminary results of an Intergroup study of patientswith locally advanced nasopharyngeal cancer show a highly significantimprovement in survival with the use of chemoradia-tion, comparedwith radiation alone, Muhyi Al-Sarraf, MD, said at the ASCO plenarysession.

Median progression-free survival is 13 months on the radiationalone arm and has not been reached in the combination arm, saidDr. Al-Sarraf, of the Providence Cancer Center, Southfield, Michigan.

Three-year progression-free survival is an estimated 65% for thecombination therapy arm vs 24% for the radiation only arm (P =.0001). Median survival is 2 years better in the combination arm(60 months vs 34 months), and estimated 3-year survival is 31%better (76% vs 45%, P = .0017.)

Nasopharyngeal carcinoma, although rare in the United States,is common across the world and is especially prevalent in southernChina, Southeast Asia, North Africa, the Middle East, and amongEskimos. The incidence in this country may be increasing due toimmigration from these areas. Migrants continue to have a higherincidence, even into the second and third generations, he said.

The experimental arm received the same radiation dose as the standardarm plus concurrent cisplatin (Platinol), 100 mg/m² givenon day 1 and every 3 weeks for 3 doses. At the end of chemoradiation,patients received an additional three courses of reduced-dosecisplatin and fluorouracil.

At present, 150 patients have been analyzed, the majority withT4 or T3 disease. An important point, Dr. Al-Sarraf said, is thatthere have been no toxicity-related deaths and no grade 5 toxicityin either arm.

Edward Vokes, MD, of the University of Chicago, said that concurrentcisplatin and radiation followed by adjuvant cis-platin/fluorouracilshould now be considered standard therapy for locoregion-allyadvanced nasopharyngeal cancer.

"Given the magnitude of the differences, both in time toprogression and survival, confirmatory trials in this diseaseare not necessary nor would they be practical," Dr. Vokessaid.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content